LONDON, July 28 (Reuters) – Generic competition to
cholesterol fighter Crestor in the key U.S. market hit
second-quarter earnings at drugmaker AstraZeneca, which
is now banking on new cancer…
The post AstraZeneca earnings hit by waning cholesterol drug sales appeared first on NASDAQ.